Cara Therapeutics to Sponsor Symposium and Present Posters at PAINWeek
September 01 2016 - 8:00AM
Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company
focused on developing and commercializing new chemical entities
designed to alleviate pain and pruritus by selectively targeting
peripheral kappa opioid receptors, today announced that it will
sponsor a lunchtime symposium titled “Moving Beyond Mu with Kappa
Opioid Receptor Agonists - Leaving the Baggage Behind” at PAINWeek,
to be held September 6-10, 2016 at the Cosmopolitan of Las Vegas.
Pain management experts will discuss the latest
developments in analgesia, including efficacy, safety, and abuse
potential results from Cara’s Phase 2 chronic osteoarthritis pain
and human abuse liability studies of CR845, the Company’s
first-in-class peripherally selective kappa opioid agonist. The
findings to be presented support the view that CR845 is unlikely to
be recreationally abused or liable to cause physical
dependence.
The symposium details are as follows:
Date: Friday, September 9,
2016Time: 12:30 – 1:30 p.m.
PTLocation: Castellana Ballroom, Level 3,
the Cosmopolitan of Las Vegas Experts:
- Joseph Stauffer, D.O., M.B.A., Chief Medical Officer, Cara
Therapeutics; Assistant Professor, Department of Anesthesiology
& Critical Care Medicine, Johns Hopkins University School of
Medicine
- Michael J. Brennan, M.D., Medical Director, the Pain Center of
Fairfield; Senior Attending Physician, Department of Medicine,
Bridgeport Hospital; Associate Director, Chronic Pain and Recovery
Program, Silver Hill Hospital
In addition, two scientific posters will be on
display in Gracia 7 on the 3rd level of the Cosmopolitan of Las
Vegas from 9:00 a.m. PT on Wednesday, September 7 through 4:30 p.m.
PT on Friday, September 9.
- Poster #122: “Preclinical and Clinical
Assessments of the Abuse Potential of the Kappa-Opioid Receptor
Agonist CR845 Suggest Low Abuse Potential”
- Poster #123: “Safety, Tolerability, and
Effectiveness of Orally Administered CR845, a Peripherally Acting
Kappa-Opioid Receptor Agonist, in Patients with Osteoarthritis of
the Knee or Hip”
A poster reception will also be held Thursday,
September 8 from 6:30 – 8:30 p.m. PT.
For more information on PAINWeek, visit:
http://www.painweek.org/.
About CR845
CR845 is a peripherally acting kappa opioid
receptor agonist currently in development for the treatment of
acute and chronic pain and pruritus. In multiple randomized,
double-blind, placebo-controlled Phase 2 trials in patients
undergoing laparoscopic hysterectomy or bunionectomy procedures,
I.V. CR845 treatment resulted in statistically significant
reductions in both pain intensity and opioid-related side effects.
In a human abuse liability trial, I.V. CR845 demonstrated
statistically significant reductions in “drug liking,” “feeling
high,” “overall liking,” and “take drug again” scores in comparison
to I.V. pentazocine, a Schedule IV analgesic.
An oral formulation of CR845 has also been
evaluated in a Phase 2a study in osteoarthritis patients and was
shown to be well tolerated with twice a day dosing for two weeks,
with evidence of decreasing pain scores during that time
period.
In more than 818 subjects dosed to date, CR845
was found to be well tolerated, without incurring the dysphoric and
psychotomimetic side effects that have been reported with centrally
acting (CNS-active) kappa opioid receptor agonists.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage
biotechnology company focused on developing and commercializing new
chemical entities designed to alleviate pain and pruritus by
selectively targeting peripheral kappa opioid receptors. Cara is
developing a novel and proprietary class of product candidates that
target the body's peripheral nervous system and have demonstrated
initial efficacy in patients with moderate-to-severe pain without
inducing many of the undesirable side effects typically associated
with currently available pain therapeutics.
INVESTOR CONTACT:
Jesse Baumgartner
Stern Investor Relations, Inc.
212-362-1200
Jesse@sternir.com
MEDIA CONTACT:
Annie Starr
6 Degrees
973-415-8838
astarr@6degreespr.com
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Apr 2023 to Apr 2024